Sanofi, Bristol shake up alliance as patents end

PARIS (Reuters) – Drugmakers Sanofi and Bristol-Myers Squibb said they plan to restructure their alliance from January 1 to respond to the loss of exclusivity on two key drugs and the arrival of generic competition in many major markets. The move will see Bristol-Myers return rights to blood clot preventer Plavix and blood pressure treatment Avapro to the French drugmaker in all markets, the companies said in a joint statement on Wednesday. This will give Sanofi sole commercial control of the two treatments, although Bristol-Myers will keep rights to Plavix in the United States and Puerto …

Bristol immune drug shows promise in three cancers

CHICAGO (Reuters) – An experimental Bristol-Myers Squibb drug helped shrink tumors in patients with advanced melanoma, kidney and lung cancers in a preliminary trial, raising hopes for yet another drug that can wake up the immune system and train it to attack cancer cells. Early-stage tests of the drug BMS-936558, known as an anti-PD-1 treatment, showed it was relatively safe and shrank tumors in three of the five cancer types studied, the team reported at the American Society of Clinical Oncology (ASCO) meeting on Saturday and published online in the New England Journal of Medicine. …